Jeff Settleman, Ph.D., Joins Pfizer to Lead Oncology Research & Development

NEW YORK–(BUSINESS WIRE)–Pfizer Inc. (NYSE: PFE) announced today that Jeff Settleman, Ph.D., will
join the company as Senior Vice President and Group Head of Oncology
Research & Development, leading all early oncology research, from
discovery to proof of concept clinical studies. Dr. Settleman, a leader
in molecularly targeted cancer therapeutics, the epigenetics of cancer
drug resistance, and personalized cancer medicine, will report directly
to Mikael Dolsten, M.D., Ph.D., Chief Scientific Officer and President
of Worldwide Research, Development and Medical at Pfizer, and will be
based in La Jolla, California.

“Dr. Settleman brings to Pfizer a breadth of experience in fundamental
cancer biology, cancer genetics, and innovative thinking related to the
role of tumor heterogeneity in the development of drug tolerance and
resistance. I look forward to seeing his expertise help Pfizer further
accelerate potential breakthroughs for people living with cancer,” said
Dr. Dolsten. “Dr. Settleman’s distinguished career in both academic
research and drug discovery will be critical to Pfizer’s continuous
pursuit of new therapeutic paradigms in cancer research.”

Dr. Settleman will join Pfizer effective July 1 from Calico Life
Sciences, where he was Distinguished Principal Investigator and Head of
Oncology Research. Prior to Calico, Dr. Settleman led Discovery Oncology
at Genentech. His distinguished career as an academic scientist started
when he was a postdoctoral fellow at the Whitehead Institute for
Biomedical Research at Massachusetts Institute of Technology in Dr.
Robert Weinberg’s laboratory, before joining the Harvard School of
Medicine faculty in 1992. During his 18 years as a member of the Harvard
faculty, Dr. Settleman was named the Laurel Schwartz Professor of
Oncology, served as Director of the Center for Molecular Therapeutics
and Scientific Director of the Massachusetts General Hospital Cancer
Center, and led the Cancer Cell Biology program of the Dana Farber
Harvard Cancer Center. He has authored more than 240 peer-reviewed
publications. Dr. Settleman received his B.A. in Neuroscience from the
University of Pennsylvania and a Ph.D. in Genetics from Yale University.

“I am privileged to be joining a world-class team of scientists who have
made many important contributions to the landscape of cancer treatments
for patients over several decades,” said Dr. Settleman. “There has never
been a more exciting time in cancer research and I look forward to
helping advance and grow a highly promising pipeline that includes a
variety of targeted therapies and immunotherapies, with opportunities
for rational combination treatments.”

Robert T. Abraham, Ph.D., who has led the Oncology Research &
Development group at Pfizer since 2011, has decided to retire at the end
of 2019. During Dr. Abraham’s tenure, ten new Pfizer oncology medicines
were approved, benefitting hundreds of thousands of patients around the
world. Pfizer’s Oncology Research and Development group is focused on
advancing next-generation cancer medicines through a diversified and
comprehensive approach to target the tumor and the tumor
microenvironment. With three distinct groups, Tumor Cell Biology, Cancer
Immunology Discovery and Targeted Therapeutics, the organization is
comprised of more than 400 dedicated scientists. Dr. Settleman will also
become site head of Pfizer’s La Jolla Research & Development hub where
nearly 800 employees work each day in support of Pfizer’s oncology
mission. As of April 30, 2019, Pfizer’s Oncology pipeline includes 44
programs from Phase 1 through Registration.

Pfizer Inc.: Working together for a healthier world®

At Pfizer, we apply science and our global resources to bring therapies
to people that extend and significantly improve their lives. We strive
to set the standard for quality, safety and value in the discovery,
development and manufacture of health care products. Our global
portfolio includes medicines and vaccines as well as many of the world’s
best-known consumer health care products. Every day, Pfizer colleagues
work across developed and emerging markets to advance wellness,
prevention, treatments and cures that challenge the most feared diseases
of our time. Consistent with our responsibility as one of the world’s
premier innovative biopharmaceutical companies, we collaborate with
health care providers, governments and local communities to support and
expand access to reliable, affordable health care around the world. For
more than 150 years, we have worked to make a difference for all who
rely on us. We routinely post information that may be important to
investors on our website at www.pfizer.com.
In addition, to learn more, please visit us on www.pfizer.com
and follow us on Twitter at @Pfizer and @Pfizer_News, LinkedIn, YouTube
and like us on Facebook at Facebook.com/Pfizer.

Pfizer Disclosure Notice

The information contained in this release is as of June 5, 2019.
Pfizer assumes no obligation to update forward-looking statements
contained in this release as the result of new information or future
events or developments.

This release contains forward-looking information about Pfizer’s
oncology pipeline, including its potential benefits, that involves
substantial risks and uncertainties that could cause actual results to
differ materially from those expressed or implied by such statements.
Risks and uncertainties include, among other things, the uncertainties
inherent in research and development, including the ability to meet
anticipated clinical endpoints, commencement and/or completion dates for
our clinical trials, regulatory submission dates, regulatory approval
dates and/or launch dates, as well as the possibility of unfavorable new
clinical data and further analyses of existing clinical data; the risk
that clinical trial data are subject to differing interpretations and
assessments by regulatory authorities; whether regulatory authorities
will be satisfied with the design of and results from the clinical
studies; whether and when any applications may be filed in any
jurisdiction for any of Pfizer’s oncology product candidates; whether
and when any such applications may be approved by regulatory
authorities, which will depend on myriad factors, including making a
determination as to whether the product’s benefits outweigh its known
risks and determination of the product’s efficacy and, if approved,
whether any such gene therapy product candidate will be commercially
successful; decisions by regulatory authorities impacting labeling,
manufacturing processes, safety and/or other matters that could affect
the availability or commercial potential of any such gene therapy
product candidate; and competitive developments.

A further description of risks and uncertainties can be found in
Pfizer’s Annual Report on Form 10-K for the fiscal year ended December
31, 2018 and in its subsequent reports on Form 10-Q, including in the
sections thereof captioned “Risk Factors” and “Forward-Looking
Information and Factors That May Affect Future Results”, as well as in
its subsequent reports on Form 8-K, all of which are filed with the U.S.
Securities and Exchange Commission and available at www.sec.gov
and www.pfizer.com.

Contacts

Media:
Jessica Smith
212-733-6213
[email protected]